Singapore, June 9 -- South Korea-based Samsung Bioepis Co. has entered into a license, development and commercialisation agreement with Nipro Corporation for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan.

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while Nipro will be responsible for commercialisation of the medicines in Japan.

"This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with Nipro, a company...